Vascular smooth muscle cell proliferation and migration play an important role in the pathophysiology of several vascular diseases including atherosclerosis. Prostaglandins which have been implicated in this process, are synthesized by two isoforms of cyclooxygenase, with the expression of the regulated Cyclooxygenase-2 isoform , increased in atherosclerotic plaques.
INTRODUCTION
Prostaglandins such as prostacyclin (PGI 2 ), thromboxane A 2 (TXA 2 ), and prostaglandin E 2 (PGE 2 ), are widely recognized as inflammatory mediators that also regulate vascular contractility.
Prostaglandins are produced by the conversion of membrane derived arachidonic acid (AA) through the enzymatic activity of Cyclooxygenase (COX). COX is a rate limiting enzyme and exists in two distinct isoforms: COX-1 which is constitutively expressed and COX-2 which can be induced by shear stress and many growth factors. This inducible isoform is expressed at sites of inflammation such as atherosclerotic lesions from native and transplanted human coronary arteries (24) , where it is found in macrophages, endothelial and in smooth muscle cells (1) .
Proliferation and migration of vascular smooth muscle cells (VSMC) in arteries play an important role in the pathophysiology of atherosclerosis, hypertension, and restenosis after angioplasty (11) .
Upon activation, VSMC proliferate, migrate into the sub endothelium and secrete extracellular matrix proteins, stabilizing the plaque and reducing the risk of complications.
Bradykinin (BK) is a peptide hormone that is formed locally in body tissues and fluids, from its plasma precursor kininogen during physiological and inflammatory processes. BK elicits several actions such as vasodilation, increased vascular permeability, and recruitment of inflammatory cells to the site of injury. All these events occur via two BK receptor subtypes, the B2 receptor (B2KR) which is constitutively expressed in VSMC and endothelial cells, and the B1 receptor (B1KR) which is induced by inflammation and injury. In endothelial cells, BK induces the activation of the endothelial nitric oxide synthase (e-NOS) with the production of nitric oxide (NO) along with the activation of phospholipase A 2 (PLA 2 ), the release of AA, and the production of prostaglandins. NO and prostaglandins act on the smooth muscle (10, 23) . In contrast, when BK interacts directly with its receptors in vascular smooth muscle cells, it induces the activation of several enzymes such as mitogen activated protein kinases (MAPKs), Protein Kinase C (PKC), 4 along with causing the generation of reactive oxygen species (ROS), cellular migration and the production of extracellular matrix proteins (9, 26, 27) .
Several studies have reported the ability of BK to regulate COX-2 expression in different cell types. In endothelial cells in culture, BK induces COX-2 mRNA expression after 4 hours of incubation (4) . In addition, in SMC from human airways, it has been shown that BK stimulates COX-2 activity and expression in a time and dose dependent manner and that this regulation is implicated in asthma (3, 18) .
Recent studies using COX-2 inhibitors have suggested that this enzyme has both pro and antiatherogenic effects (16) . This apparent contradiction can be understood by considering that certain tissues express more of one isoform than the other (platelets express mainly COX-1, while vascular tissue express mainly COX-2). In addition, depending on the localization, each isoform synthesizes preferably one product over others (TXA 2 in platelets vs PGI 2 in vascular smooth muscle cells). Another important consideration is the time frame of COX-2 expression (initial/acute or late/chronic) within the atheromatous plaque. The regulation of COX-2 function on vascular smooth muscle cells from vessels subjected to high pressure has not been fully studied and its elucidation will help to understand the role of this enzyme in atheromatosis. Considering the relevant participation of BK on the production of prostaglandins in vascular function and its potential role in the development of the atherosclerotic plaque, we hypothesize that BK participates in the regulation of COX-2 expression in aortic vascular smooth muscle cells.
In this study we examined the modulation of COX-2 protein levels by BK in primary cultured vascular smooth muscle cells. In addition we further elucidated the signaling pathways involved in this process, including the contribution of reactive oxygen species as signaling mediators. Peroxidase activity was visualized with 3,3´-diaminobenzidine and hydrogen peroxidase.
MATERIAL AN METHODS

VSMC
Sections were counterstained with hematoxylin.
VSMC cultured in coverslips, were fixed in 4% paraformaldehyde, 0.1% glutaraldehyde, dehydrated and stained for COX-2 using the same procedure as for tissue slices. Sections and cells were observed and photographed on a Nikon Eclipse 600 microscope with a Nikon DXM1200 digital photographic system (Nikon Corporation. Tokyo, Japan). folds of control respectively compared to BK= 3.58±0.65 folds of control) (figure 6). To confirm that these cells were producing NO we measured nitrites and found a two fold increase in these metabolites after the incubation with BK (12.3+/-0.9 vs 24.9+/-3.5 nmol/mg respectively). This increase was blocked when cells were preincubated with L-NAME. To identify the origin of NO, we also measured the presence of nNOS and iNOS, observing an intense band for nNOS and a rather faint band for iNOS in these cells (data not shown).
BK induces COX-2 protein levels via the B2 receptor.
To determine which of the two receptors for BK mediates the signaling that induces COX-2 protein levels, we pre-incubated VSMC for 30 minutes with the B2KR specific antagonist HOE- confirming the previous result.
DISCUSSION
COX-2 has long been considered an inducible enzyme that is not present in normal conditions.
The finding of immunoreactivity for COX-2 in a normal artery is consistent with previous observations in normal kidney (29) where sporadic cells showed positive staining in the renal cortex. In the kidney, this expression can be increased by several stimuli such as adrenalectomy (28), extra-cellular calcium concentrations (30) and also BK (20) . Similarly, we have observed that BK can increase COX-2 immunostaining and protein levels in VSMC.
In a previous report (26), we have demonstrated that BK induces the activation of MAPK p42/p44 with a maximum at 5-10 minutes. This early activation has been considered enough to activate the signaling cascade that follows. In fact preliminary data has shown that 2 minutes of BK in the medium is enough to induce MAPK phosphorylation, maintaining the maximum at 5-10 minutes. In this report, we investigated whether BK activates this same pathway to increase COX-2 protein levels. Our observations that UO-126 but not SB-203580 decreases COX-2 levels in response to BK suggest that MAPK p42/p44, but not p38 MAPK are mediating the effects of BK in this process. At this same time frame MAPK p42/p44 phosphorylation in response to BK was not different from control. Our results differ from observations of other investigators in cells from the thick ascending limb of the Loop of Henle (5) or from human pulmonary artery smooth muscle cells (4), where they found that p38 MAPK was mediating COX-2 induction. We speculate that origin of VSMC (pulmonary artery versus aorta) or cell type could explain these differences.
It has been reported that BK, through its receptors, can activate different G proteins such as Gq, Gi or Gs (14) ; for this reason, we have studied the participation of a pathway mediated by the activation of Gs, the cAMP/PKA pathway, on the induction COX-2 by BK on aortic smooth muscle cells. In agreement with reports by Bradbury et al. (3) in pulmonary artery smooth muscle cells, our results using the adenylate cyclase inhibitor 2'-5'-dideoxyadenosine, suggested the participation of c-AMP in the pathway that leads to COX-2 expression. Surprisingly H-89, a PKA inhibitor, did not block BK-induced COX-2 levels, in fact cells expressed more COX-2 when this enzyme was blocked, even in the absence of BK. The results make us speculate that at the concentrations used in our experiments H89 could be inhibiting other kinases in addition to PKA such as MSK1 or S6K1 (8) , and that these inhibitions could be producing a more complex regulatory loop.
With regard to the pathway activated by Gq, we studied the effect of PKC and NOS inhibition on COX-2 levels. In this case, the inhibition of the increase in COX-2 levels by BK in the presence of BIM I (a PKC inhibitor), and L-NAME (a nitric oxide synthase inhibitor) suggested the participation of these enzymes in the pathway leading to COX-2 production. Although we have previously demonstrated the presence of PKC-β1 and 2, ε and ζ  in VSMC (6) , and that PKC-ε has been suggested as the mediator for BK effect on COX-2 expression in airway smooth muscle cells (19) , the determination of which of these isoforms is mediating the expression of COX-2 was beyond the aims of this report. In relation to NOS, NO has been involved as a signaling molecule in the pathway leading to COX-2 induction in bone cells (12, 17) . In VSMC, NO can be synthesized by the neuronal form of NOS, which has been described to be present in normal conditions in this cell type (22) or by the inducible form of NOS which is rapidly stimulated under inflammatory conditions (21), according to our results both isoforms could be contributing to the production of NO.
The inducible B1KR is expressed in pathological conditions, whereas the B2KR is expressed constitutively and is believed to participate in the physiological functions of the vessel wall. The stimulatory effect of BK on COX-2 levels was inhibited by the B2KR antagonist but not by the 12 B1KR antagonist. These observations suggest that the B2KR mediates BK effects in VSMC and are in agreement with a recent report, which showed that the B2 receptor is necessary for full expression of COX-2 in kidney (13).
Our previous results (27) demonstrated that BK induces an increase in ROS production with a maximum at 30 minutes. This early stimulus has been considered enough to activate the signaling cascade that follows, for this reason we did not study ROS production at 24 hours of stimulation.
Having previously reported that BK induces the production of ROS in these cells (27) , we wanted to determine whether ROS were participating in the signaling pathway activated by BK to increase COX-2 levels. Although, several studies have reported the participation of ROS on COX-2 expression (2), neither LA an oxidant scavenger, nor DPI which has been considered a NADPH oxidase inhibitor, blocked the stimulatory effect of BK on COX-2 levels. These results suggest us that ROS are not participating on the pathway that leads to increase COX-2 levels.
Our study has investigated the regulation of bradykinin on COX-2 levels in smooth muscle cells from aorta, a vessel that is permanently under high pressure and consequently at risk from developing atheromatous plaques. Although the participation of COX-2 in inflammation and other pathological conditions is well known, its pro or anti atherogenic properties are poorly defined. Macrophages COX-2 has inflammatory and pro-atherogenic properties, and its derived prostaglandins are related to the instability of the plaque (7). However, COX-2 from endothelial cells, is related to prostacyclin synthesis, is anti-thrombotic and anti-atherogenic. Along with macrophages and endothelial cells from the atheroma COX-2 is also expressed in VSMC. We demonstrated that bradykinin can induce the expression of COX-2 in VSMC and postulate that prostaglandins derived from COX-2 may regulate VSMC proliferation and/or extracellular matrix synthesis, which could result in the stabilization of the plaque and a lower probability of rupture.
13
This study suggests a role for BK on the evolution of the atheromatous plaque by virtue of controlling the levels of COX-2.
Our observations support the conclusions that: 1) BK increases COX-2 protein levels in vascular smooth muscle cells, 2) the increase in COX-2 protein is mediated by the B2 kinin receptor, MAPK p42/p44, PKC, and NOS, 3) reactive oxygen species are not important regulators of COX-2 levels in this pathway. The role of COX-2 in the atheroma may be cell type specific, and we suggest that the equilibrium between macrophages, endothelium and VSMC, will determine the final effect of COX-2 in the development of the plaque.
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